Here Are Tuesday’s Top Wall Street Analyst Research Calls: Boston Scientific, Clorox, CrowdStrike, Exxon Mobil, Honeywell International, Intuit, Intuitive Surgical, Levi Strauss, and More
24/7 Wall St. lists Tuesday analyst calls. Bank of America upgraded Honeywell (HON) to Neutral and set $265, while UBS upgraded Intuitive Surgical (ISRG) to Buy with $550. Downgrades include Clorox (CLX) to Hold with $98, Intuit (INTU) to Hold with $304, and Exxon (XOM) to Neutral with $158. Initiations: CrowdStrike (CRWD) Buy $230, Boston Scientific (BSX) Buy $74.
How this was made
The 30-second read
Why it matters
For traders, the actionable element is the explicit rating and price-target changes across multiple US-listed names, which can drive short-term flows and volatility at the open.
Market read
This is a positioning-driven catalyst set for multiple US stocks, not a single-company fundamental update.
What to watch
The article provides no thesis details, so traders should treat these as sentiment/positioning signals and verify whether the underlying analyst rationale is consistent with recent fundamentals.
Background
The piece is a multi-stock roundup of analyst upgrades, downgrades, and initiation notes for Tuesday, alongside a brief macro market wrap.
Ticker impact
Honeywell was upgraded to Neutral from Underperform by Bank of America, with a raised target to $265 from $205.
Mildly positive bias for the session and following days, with follow-through dependent on broader tape.
The article provides an explicit rating change and target increase, which typically moves short-term positioning, but no new operational data is disclosed.
International Paper was upgraded to Overweight from Neutral at JPMorgan, with a $51 target price.
Slight positive drift versus peers over the next few sessions.
The text contains a clear rating change and PT, but lacks thesis details beyond the PT itself.
Intuitive Surgical was upgraded to Buy from Neutral at UBS, lifting the target to $550 from $500.
Potential upside reaction, especially if the market is already favoring med-tech.
The article discloses a concrete upgrade and PT change, which is actionable for traders, but provides no new company-specific catalyst.
Magnolia Oil & Gas was upgraded to Buy from Hold at Truist, with the target nudged to $33 from $32.
Limited upside bias; magnitude likely smaller than for larger PT revisions.
The PT change is minor and the article provides no additional fundamental drivers.
Zimmer Biomet was double upgraded to Buy from Sell at UBS, raising the target to $115 from $89.
Higher probability of a stronger positive reaction than typical upgrades.
The PT jump is substantial and the rating change is from Sell to Buy, which often drives immediate sentiment shifts.
Albertsons was downgraded to Neutral from Buy at UBS, cutting the target to $12 from $20.
Near-term negative bias, with potential for continued weakness if the market treats it as a thesis reset.
The article includes a clear downgrade and a large target reduction, both typically bearish for positioning.
Clorox was downgraded to Hold from Buy at Jefferies, with the target cut to $98 from $125.
Mild-to-moderate downside pressure over the next few sessions.
The PT cut is large, but the article does not provide the underlying rationale, limiting conviction.
Exxon Mobil was downgraded to Neutral from Buy at Bank of America, with the target raised to $158 from $154.
Mixed reaction possible; PT increase may offset downgrade initially.
The direction of the rating conflicts with the PT change, and the article provides no thesis to reconcile it.
Market effects
Analyst actions skew toward med-tech and software (ISRG, BSX, CRWD, INTU), with consumer and energy also represented.
Primarily US-listed single-name sentiment; no direct cross-market linkage beyond macro backdrop.
Limited, as the disclosed items are US analyst rating changes rather than global policy or deal news.
Counterpoint
Rating changes may be quickly discounted if they lack new fundamental evidence; large PT cuts (INTU) can be more about valuation than near-term earnings.
Key entities
- companyBoston Scientific
Assumed with a Buy rating at UBS, with the target cut to $74 from $95.
- companyClorox
Downgraded to Hold from Buy at Jefferies, with the target cut to $98 from $125.
- companyCrowdStrike
Initiated with a Buy rating at Loop Capital, with a $230 target.
- companyExxon Mobil
Downgraded to Neutral from Buy at Bank of America, with the target raised to $158 from $154.
- companyHoneywell International
Upgraded to Neutral from Underperform at Bank of America, with the target raised to $265 from $205.
